(NASDAQ: LXRX) Lexicon Pharmaceuticals's forecast annual revenue growth rate of -1.58% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Lexicon Pharmaceuticals's revenue in 2025 is $31,213,000.On average, 3 Wall Street analysts forecast LXRX's revenue for 2025 to be $7,626,738,000, with the lowest LXRX revenue forecast at $2,215,385,800, and the highest LXRX revenue forecast at $18,449,442,400. On average, 4 Wall Street analysts forecast LXRX's revenue for 2026 to be $5,132,431,496, with the lowest LXRX revenue forecast at $2,723,835,000, and the highest LXRX revenue forecast at $9,987,395,000.
In 2027, LXRX is forecast to generate $12,849,237,640 in revenue, with the lowest revenue forecast at $3,232,284,200 and the highest revenue forecast at $24,659,786,200.